AI litigation brief
Ozempic Gastroparesis remains mid-stage / active mdl with 5 current signals in the accepted feed.
Overview
PACER court filing on Mar 11: Blewett v. ELI LILLY AND COMPANY. This is the lead item in the current accepted signal set.
Key developments
- PACER court filing on Mar 11: Blewett v. ELI LILLY AND COMPANY
Trajectory
Ozempic Gastroparesis is moving on the court side on MDL 3094 — docket scheduling and case-management orders should lead the next editorial update.
Editorial intelligence
MDL 3094 should stay on the lead docket watch because it is the primary consolidation vehicle for Ozempic Gastroparesis.
Generated Mar 11, 2026, 10:16 PM UTC